<DOC>
	<DOCNO>NCT00625092</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Hyperthermia therapy kill tumor cell heat several degree normal body temperature . Peritoneal infusion heat nonheated chemotherapy drug surgery may kill tumor cell . PURPOSE : This phase I trial study side effect best dose hyperthermic intraperitoneal oxaliplatin follow intraperitoneal leucovorin fluorouracil treat patient peritoneal cancer .</brief_summary>
	<brief_title>Hyperthermic Intraperitoneal Oxaliplatin Peritoneal Malignancies</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety optimal dose hyperthermic intraperitoneal oxaliplatin administer cytoreductive surgery follow intraperitoneal leucovorin calcium fluorouracil patient peritoneal malignancy . Secondary - To determine outcome cytoreductive surgery patient . - To determine time disease progression pattern failure patient treat regimen . - To determine 1 5 year survival patient treat regimen . - To compare quality-of-life pre- post-surgery patient . - To characterize total- free-platinum pharmacokinetics plasma total platinum intraperitoneal space baseline , , hyperthermic intraperitoneal chemotherapy ( HIPC ) . - To assess presence genetic polymorphism XDP XRCC1 DNA repair gene . - To assess tumor normal tissue concentration total platinum obtain baseline immediately HIPC . OUTLINE : - Cytoreductive Surgery : Patients undergo exploratory laparotomy remove tumor nodule peritoneal surface prior gastrointestinal anastomosis . An intraperitoneal drain place postoperative intraperitoneal chemotherapy . - Hyperthermic peritoneal chemotherapy ( HIPC ) : After cytoreductive surgery , intestinal anastomosis , patient receive oxaliplatin abdomen cavity approximately 1 liter/min 41-42º C hold 30 minute maximum tolerate dose . A heat exchanger maintain fluid temperature 44-46º C maintain intraperitoneal temperature 41-42º C. Patients may receive fluid challenge , furosemide , mannitol , renal dose dopamine maintain brisk diuresis discretion anesthesiologist . - Intraperitoneal chemotherapy : After HIPC , patient receive leucovorin calcium intraperitoneally intraperitoneal drain remain 2 hour drain . Patients receive fluorouracil intraperitoneally intraperitoneal drain day 1 remain peritoneal fluid 23 hour drain . The infusion repeat day 2 . Blood sample collect prior surgery pharmacogenetic study analyze presence genetic polymorphism XPD XRCC1 DNA repair gene GSTP1 GSTM1 glutathione-S-transferase enzyme ( i.e. , XPD , Asp312Asn , XPD K751Q , XRCC1 Arg399GIn , XRCC1 Arg399Q , GSTP1 l105V , GSTM1 DEL ) . Blood sample also collect periodically pharmacokinetic study analyze oxaliplatin concentration . Normal tumor tissue collect periodically analyzed total platinum concentration . Quality life assess baseline 4 , 8 , 12 month . After completion study treatment , patient follow every 4 month 2 year every 6 month least 5 year .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Inclusion criterion : Patients must histologic proof peritoneal metastasis ( include adenomucinosis ) Complete tumor resection possible ( may include liver metastasis treatable resection radiofrequency ablation ) Patients may receive previous chemotherapy ( except peritoneal ) and/or immunotherapy . If previous chemotherapy , least 4 week must pass since last dose . Patients may receive previous radiation therapy , however radiation large bowel , small bowel and/or stomach make patient ineligible study . Patients must Karnofsky performance score ≥ 80 % . Adequate hematologic , renal hepatic function within 14 day registration define : White blood count ( WBC ) ≥ 3,000 platelet count ≥ 70,000 , serum bilirubin ≤ 2.0 mg/dL , serum creatinine ≤ 1.5 mg/dL Patients must least 18 year age Patients must able provide inform consent Exclusion criterion : Metastatic disease present outside peritoneal cavity Diagnosis mesothelioma Grade 2 high sensory neuropathy time study enrollment History allergic reaction platinum compound Pregnant lactate woman . Pregnancy contraindication receive therapy , thus relevant , patient require use effective birth control . The agent use study include pregnancy category D clear evidence risk pregnancy . There information excretion agent breast milk therefore patient must refrain breastfeed receive study therapy . Previous peritoneal chemotherapy . Patients uncontrolled concurrent medical problem ( i.e . diabetes mellitus ) history uncontrolled cardiovascular disease ( history hospitalization acute myocardial infarction congestive heart failure ( CHF ) within 3 month prior registration ) . Patients psychiatric addictive disorder preclude obtain inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>